HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Comparison of accelerated and rapid schedules for monovalent hepatitis B and combined hepatitis A/B vaccines in children with cancer.

Abstract
The aim of this study was to determine the efficacy of immunization against hepatitis A and B infections with "rapid" or "accelerated" schedules in children with cancer receiving chemotherapy. Fifty-one children were recruited to receive either vaccination schedule, in the "rapid vaccination schedule"; hepatitis B (group I) or combined hepatitis A/B vaccines (group III) were administered at months 0, 1, 2, and 12; in the "accelerated vaccination schedule," hepatitis B (group II) or combined hepatitis A/B (group IV) vaccines were administered on days 0, 7, 21, and 365 intramuscularly. The seroconversion rates at months 1 and 3 were 35.7 and 57.1% in group I and 25 and 18.8% in group II, respectively. Group I developed higher seroconversion rates at month 3. In group III the seroconversion rates for hepatitis B at months 1 and 3 were 54.5 and 60% and in group IV 50 and 70%, respectively. For hepatitis A, the seroconversion rates at months 1 and 3 were 81.8 and 90% in group III and 80 and 88.9% in group IV, respectively. The accelerated vaccination schedule seems to have no advantage in children receiving cancer chemotherapy except for high antibody levels at month 1. In conclusion, the accelerated vaccination schedules are not good choices for cancer patients. The combined hepatitis A/B vaccine is more effective than monovalent vaccine in cancer patients, which probably can be explained by an adjuvant effect of the antigens. The seroconversion of hepatitis A by the combined hepatitis A/B vaccination is very good in cancer patients.
AuthorsYavuz Köksal, Ali Varan, G Burca Aydin, Neriman Sari, Nalan Yazici, Bilgehan Yalcin, Tezer Kutluk, Canan Akyuz, Münevver Büyükpamukçu
JournalPediatric hematology and oncology (Pediatr Hematol Oncol) Vol. 24 Issue 8 Pg. 587-94 (Dec 2007) ISSN: 1521-0669 [Electronic] England
PMID18092249 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
Topics
  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Hepatitis A (blood, etiology, immunology, prevention & control)
  • Hepatitis A Antibodies (blood, immunology)
  • Hepatitis A Vaccines (administration & dosage, immunology)
  • Hepatitis B (blood, immunology, prevention & control)
  • Hepatitis B Antibodies (blood, immunology)
  • Hepatitis B Vaccines (administration & dosage, immunology)
  • Humans
  • Injections, Intramuscular
  • Male
  • Neoplasms (blood, complications, drug therapy, immunology)
  • Prospective Studies
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: